Jones Financial Companies Lllp grew its stake in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 14.4% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 572,013 shares of the company’s stock after purchasing an additional 72,121 shares during the quarter. Jones Financial Companies Lllp’s holdings in Kenvue were worth $9,392,000 at the end of the most recent quarter.
Several other institutional investors also recently added to or reduced their stakes in KVUE. TrueMark Investments LLC increased its holdings in Kenvue by 8.8% during the 2nd quarter. TrueMark Investments LLC now owns 229,648 shares of the company’s stock worth $4,807,000 after purchasing an additional 18,623 shares during the period. Vanguard Group Inc. increased its stake in shares of Kenvue by 1.8% during the second quarter. Vanguard Group Inc. now owns 233,246,267 shares of the company’s stock valued at $4,881,844,000 after buying an additional 4,101,880 shares during the period. OFI Invest Asset Management raised its holdings in shares of Kenvue by 705.6% in the second quarter. OFI Invest Asset Management now owns 26,979 shares of the company’s stock valued at $565,000 after acquiring an additional 23,630 shares in the last quarter. Simplicity Wealth LLC purchased a new stake in Kenvue in the second quarter worth about $507,000. Finally, Aberdeen Group plc lifted its stake in Kenvue by 15.1% in the second quarter. Aberdeen Group plc now owns 766,450 shares of the company’s stock worth $16,015,000 after acquiring an additional 100,403 shares during the period. Hedge funds and other institutional investors own 97.64% of the company’s stock.
Insider Buying and Selling
In related news, Director Jeffrey C. Smith purchased 3,200,000 shares of Kenvue stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average cost of $17.37 per share, for a total transaction of $55,584,000.00. Following the completion of the transaction, the director owned 27,307,632 shares in the company, valued at $474,333,567.84. The trade was a 13.27% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. 1.68% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
Read Our Latest Report on Kenvue
Kenvue Stock Performance
Shares of NYSE KVUE opened at $17.99 on Thursday. The company has a 50 day simple moving average of $17.20 and a two-hundred day simple moving average of $17.93. The stock has a market cap of $34.47 billion, a price-to-earnings ratio of 23.99 and a beta of 0.59. The company has a current ratio of 0.98, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 12 month low of $14.02 and a 12 month high of $25.17.
Kenvue (NYSE:KVUE – Get Free Report) last posted its earnings results on Monday, November 3rd. The company reported $0.28 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.27 by $0.01. The company had revenue of $3.76 billion during the quarter, compared to the consensus estimate of $3.83 billion. Kenvue had a net margin of 9.55% and a return on equity of 20.02%. The firm’s quarterly revenue was down 3.5% on a year-over-year basis. During the same period in the previous year, the firm posted $0.28 earnings per share. As a group, analysts predict that Kenvue Inc. will post 1.14 earnings per share for the current year.
Kenvue Dividend Announcement
The business also recently announced a quarterly dividend, which will be paid on Wednesday, February 25th. Stockholders of record on Wednesday, February 11th will be paid a $0.2075 dividend. The ex-dividend date is Wednesday, February 11th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. Kenvue’s dividend payout ratio is presently 110.67%.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Further Reading
- Five stocks we like better than Kenvue
- The day the gold market broke
- Buffett, Gates and Bezos Quietly Dumping Stocks—Here’s Why
- Trump Planning to Use Public Law 63-43: Prepare Now
- Forget AI, This Will Be the Next Big Tech Breakthrough
- What a Former CIA Agent Knows About the Coming Collapse
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
